Abstract
The objectives were to evaluate the safety and oncologic efficacy of primary robotic retroperitoneal lymph node (R-RPLND) dissection for testicular germ cell tumors. A retrospective analysis was performed on all primary R-RPLND cases performed by a single surgeon, who performs both open and R-RPLND at a high-volume academic institution, between August 2013 and August 2019. Data on patient demographics, operative techniques, perioperative outcomes, and tumor characteristics were obtained. 28 men were identified who underwent primary R-RPLND. The majority of patients (N = 21, 75%) had clinical stage I disease, and a bilateral template was more commonly performed than either single side alone (N = 13, 46%). Of note, two cases involving clinical stage II disease were converted electively from robotic to open procedures at the discretion of the surgeon. R-RPLND patients experienced no intraoperative complications. The median follow-up time was 8 months (interquartile range 4–29 months). One (4%) patient developed a disease recurrence at 10 months after R-RPLND. Conclusion: primary R-RPLND is a safe and efficacious procedure for carefully selected men with stage I and II non-seminomatous germ cell tumors of the testis. Long-term data are needed to evaluate the comparative oncologic efficacy with open surgery and the notably high rate of chylous ascites.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cancer of the testis. Cancer Stat Facts. In: SEER. https://seer.cancer.gov/statfacts/html/testis.html. Accessed 21 Oct 2019
Diagnosis and treatment of early stage testicular cancer: AUA Guideline (2019) American Urological Association. https://www.auanet.org/guidelines/testicular-cancer-guideline. Accessed 21 Oct 2019
Motzer RJ, Jonasch E, Agarwal N et al (2015) Testicular cancer, Version 2.2015. J Natl Compr Canc Netw 13:772–799. https://doi.org/10.6004/jnccn.2015.0092
Schwen ZR, Gupta M, Pierorazio PM (2018) A review of outcomes and technique for the robotic-assisted laparoscopic retroperitoneal lymph node dissection for testicular cancer. Adv Urol 2018:2146080. https://doi.org/10.1155/2018/2146080
Werntz R, Pearce S, Eggener S (2018) Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection. Curr Opin Urol 28:461–468. https://doi.org/10.1097/MOU.0000000000000530
Subramanian VS, Nguyen CT, Stephenson AJ, Klein EA (2010) Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Urologic Oncology: Seminars and Original Investigations 28:504–509. https://doi.org/10.1016/j.urolonc.2008.10.026
Davol P, Sumfest J, Rukstalis D (2006) Robotic-assisted laparoscopic retroperitoneal lymph node dissection. Urology 67:199. https://doi.org/10.1016/j.urology.2005.07.022
Pearce SM, Golan S, Gorin MA et al (2017) Safety and early oncologic effectiveness of primary robotic retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. Eur Urol 71:476–482. https://doi.org/10.1016/j.eururo.2016.05.017
Calaway AC, Einhorn LH, Masterson TA et al (2019) Adverse surgical outcomes associated with robotic retroperitoneal lymph node dissection among patients with testicular cancer. Eur Urol 76:607–609. https://doi.org/10.1016/j.eururo.2019.05.031
Rocco NR, Stroup SP, Abdul-Muhsin HM et al (2019) Primary robotic RLPND for nonseminomatous germ cell testicular cancer: a two-center analysis of intermediate oncologic and safety outcomes. World J Urol. https://doi.org/10.1007/s00345-019-02900-w
Nayan M, Jewett MAS, Sweet J et al (2015) Lymph node yield in primary retroperitoneal lymph node dissection for nonseminoma germ cell tumors. J Urol 194:386–391. https://doi.org/10.1016/j.juro.2015.03.100
Harris KT, Gorin MA, Ball MW et al (2015) A comparative analysis of robotic vs laparoscopic retroperitoneal lymph node dissection for testicular cancer. BJU Intern 116:920–923. https://doi.org/10.1111/bju.13121
Tselos A, Moris D, Tsilimigras DI et al (2018) Robot-assisted retroperitoneal lymphadenectomy in testicular cancer treatment: a systematic review. J Laparoendosc Adv Surg Tech 28:682–689. https://doi.org/10.1089/lap.2017.0672
Williams SB, McDermott DW, Winston D et al (2010) Morbidity of open retroperitoneal lymph node dissection for testicular cancer: contemporary perioperative data. BJU Int 105:918–921. https://doi.org/10.1111/j.1464-410X.2009.08888.x
Cary C, Foster RS, Masterson TA (2019) Complications of retroperitoneal lymph node dissection. Urol Clin North Am 46:429–437. https://doi.org/10.1016/j.ucl.2019.04.012
Baniel J, Foster RS, Rowland RG et al (1994) Complications of primary retroperitoneal lymph node dissection. J Urol 152:424–427. https://doi.org/10.1016/S0022-5347(17)32754-4
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Andrew Supron, Joseph Cheaib, Michael Biles, Zeyad Schwen, Mohamad Allaf, and Phillip Pierorazio declare that they have no conflict of interest.
Ethical approval
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. A waiver of informed consent was obtained from our institutional review board (IRB) for this study.
Human and animal rights statement
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Supron, A.D., Cheaib, J.G., Biles, M.J. et al. Primary robotic retroperitoneal lymph node dissection following orchiectomy for testicular germ cell tumors: a single-surgeon experience. J Robotic Surg 15, 309–313 (2021). https://doi.org/10.1007/s11701-020-01107-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11701-020-01107-1